These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25953090)

  • 1. Decreased serum HDL at initial diagnosis correlates with worse outcomes for triple-negative breast cancer but not non-TNBCs.
    Fan Y; Ding X; Wang J; Ma F; Yuan P; Li Q; Zhang P; Xu B
    Int J Biol Markers; 2015 May; 30(2):e200-7. PubMed ID: 25953090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes.
    Lofterød T; Mortensen ES; Nalwoga H; Wilsgaard T; Frydenberg H; Risberg T; Eggen AE; McTiernan A; Aziz S; Wist EA; Stensvold A; Reitan JB; Akslen LA; Thune I
    BMC Cancer; 2018 Jun; 18(1):654. PubMed ID: 29902993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
    Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
    Bouchalova K; Svoboda M; Kharaishvili G; Vrbkova J; Bouchal J; Trojanec R; Koudelakova V; Radova L; Cwiertka K; Hajduch M; Kolar Z
    Tumour Biol; 2015 Jun; 36(6):4243-52. PubMed ID: 25616695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast-conserving therapy for triple-negative breast cancer.
    Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
    JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
    Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
    PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-negative breast cancer: An institutional analysis.
    Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK
    Indian J Cancer; 2014; 51(2):163-6. PubMed ID: 25104201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of body mass index on clinical outcomes in triple-negative breast cancer.
    Ademuyiwa FO; Groman A; O'Connor T; Ambrosone C; Watroba N; Edge SB
    Cancer; 2011 Sep; 117(18):4132-40. PubMed ID: 21387276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Syndrome: does this influence breast cancer outcomes in the triple-negative population?
    Kennard K; Buckley ME; Sizer LM; Larson S; Carter WB; Frazier TG; Carp NZ
    Breast Cancer Res Treat; 2021 Feb; 186(1):53-63. PubMed ID: 33389405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment TG/HDL-C Ratio Is Superior to Triacylglycerol Level as an Independent Prognostic Factor for the Survival of Triple Negative Breast Cancer Patients.
    Dai D; Chen B; Wang B; Tang H; Li X; Zhao Z; Li X; Xie X; Wei W
    J Cancer; 2016; 7(12):1747-1754. PubMed ID: 27698913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-negative breast cancer survival in Iranian patients.
    Aghili M; Lashkari M; Farrokhpey AH; Izadi S
    Acta Med Iran; 2013 Sep; 51(8):560-6. PubMed ID: 24026994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.
    Mori H; Kubo M; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Miyazaki T; Oda Y; Otsuka T; Nakamura M
    PLoS One; 2016; 11(12):e0167016. PubMed ID: 27977696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC).
    Cho EY; Chang MH; Choi YL; Lee JE; Nam SJ; Yang JH; Park YH; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):753-61. PubMed ID: 21170648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
    Podo F; Santoro F; Di Leo G; Manoukian S; de Giacomi C; Corcione S; Cortesi L; Carbonaro LA; Trimboli RM; Cilotti A; Preda L; Bonanni B; Pensabene M; Martincich L; Savarese A; Contegiacomo A; Sardanelli F
    Clin Cancer Res; 2016 Feb; 22(4):895-904. PubMed ID: 26503945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
    Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
    Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body mass index, diabetes, and triple-negative breast cancer prognosis.
    Tait S; Pacheco JM; Gao F; Bumb C; Ellis MJ; Ma CX
    Breast Cancer Res Treat; 2014 Jul; 146(1):189-97. PubMed ID: 24869799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.